NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Erasca, Inc. (ERAS) Stock Analysis

Erasca, Inc. (ERAS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ERAS

$14.49

−$0.13 (−0.89%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ERAS with… →

ERAS Key Statistics

As of Oct 21, 2026
Trading
Open
$14.71
Previous Close
$14.62
Day's Range
14.38–15.05
52-Week Range
2.11–24.28
Volume
3.84M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.62
Valuation
Market Cap
$5.07B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.95
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$124.55M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
349.76M
1-Year Return
+508.82%
Dividend and dates
Earnings Date
November 11, 2026estimated
Avg Volume
4.35M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ERAS closed at $14.49, +508.82% over 1 year.

Erasca, Inc. (ERAS) has a market capitalization of $5.07B.

In fiscal 2025, ERAS reported revenue of $0.00.

ERAS Stock Return by Calendar Year

Erasca, Inc. (ERAS) return since Jul 2021: what $10,000 became

1 year
$10,000 $60,882
+508.82%
5 years
$10,000 $7,492
−25.08%
Since Jul 2021
$10,000 $8,313
−16.87%

If you had invested $10,000 in Erasca, Inc. (ERAS) at the close on July 16, 2021, the earliest close on record here, it would have been worth $8,313 at the close on October 21, 2026: −16.87% in total, −3.45% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+289.52%
2025+48.21%
2024+17.84%
2023−50.58%
2022−72.34%
2021 (partial year)−10.61%

As of October 21, 2026.

ERAS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$124.55M—
2024$0.00−$161.65M—
2023$0.00−$125.04M—
2022$0.00−$242.81M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$131.41M−$124.55M—
2024$0.00—−$157.09M−$161.65M—
2023$0.00—−$141.53M−$125.04M—
2022$0.00—−$145.45M−$242.81M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Erasca, Inc. (ERAS) is capitalised at $5.07B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 103 employees.

ERAS last closed at $14.49 on October 21, 2026. That is −$0.13 (−0.89%) against the previous close. Over the past 52 weeks the price has ranged from $2.11 to $24.28. The latest close sits 588.36% above that 52-week low.

Financial Health

In fiscal 2025, Erasca, Inc. reported revenue of $0.00. The same year closed with a net loss of $124.55M. Trailing earnings per share are −0.95.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is +508.82%. Across 5 years the annualized return works out at −5.61%. Beta against the wider market is reported at 0.62. Daily returns over the trailing 5 years annualize to a volatility of 82.88%.

Growth & Income

No dividend is on file for ERAS.

2026 is still running; the total return is +289.52% year to date. The strongest complete calendar year on file is 2025 at +48.21%; the weakest is 2022 at −72.34%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Erasca, Inc. (ERAS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Erasca, Inc. ERAS $5.07B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Erasca, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Erasca, Inc.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Visit website →